Cipla Docetaxel 20mg. 80mg Injection
PDF Leaflet Revision Date: 04 March 2011
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of various cancers including breast, lung, ovarian, and prostate cancer.
Dosage (summary)
75 mg/mu00b2 for breast and lung cancer; 100 mg/mu00b2 for ovarian cancer; 75 mg/mu00b2 for prostate cancer.
Special Populations
- Hepatic impairment
- Elderly
- Children
Pregnancy & Breastfeeding
Contraindicated due to teratogenic effects.
Key Drug Interactions
- CYP3A4 inhibitors
- Ciclosporin
- Ketoconazole
Contraindications
- Hypersensitivity to docetaxel
- Neutrophil count < 1500 cells/mmu00b3
- Severe liver impairment
Common side effects
- Neutropenia
- Hypersensitivity reactions
- Fluid retention
- Gastrointestinal effects
Counselling Points
- Monitor for hypersensitivity reactions
- Premedication with dexamethasone recommended
- Avoid pregnancy during treatment
Serious warnings
- Severe hypersensitivity reactions
- Increased treatment-related mortality in liver impairment
- Monitor liver function
Important Disclaimer
The Cipla Docetaxel 20mg. 80mg Injection professional information leaflet below is the property of Cipla and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
